@Supermatt Bub has secured entry to US then why can't it get approved to China? Is chinese health standards more rigorous than US? I am not sure if you have listened to strategic review webcast. It is clearly mentioned that despite it being costly and time consuming process, company will still work for obtaining SAMR approval. Also they mentioned that unlike the previous management putting all eggs in one basket, they will supply to China with multiple channels and multiple suppliers. With all those initiatives, I am assuming revenue from China will significantly increase in 2023-24. Also revenue from US will significantly increase as per recent surge in sell on amazon and other platforms.
Ann: Strategic Review - Presentation, page-46
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BUB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.010(8.33%) |
Mkt cap ! $116.1M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $669.0K | 5.144M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 522245 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 668951 | 13 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BUB (ASX) Chart |